What is the half-life of SS-31 (Elamipretide)?

SS-31 (Elamipretide) has a half-life of ~4 hours, which is why it's typically administered Once daily for optimal therapeutic effect.

How do I reconstitute SS-31 (Elamipretide)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Anti-Ageing

Preclinical

SS-31 (Elamipretide)

Also known as: Elamipretide, MTP-131, Bendavia, NAD+ Precursor Peptide

Overview

Key Facts

Primary Goal: A mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin to stabilize electron transport chain function

A mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin to stabilize electron transport chain function. SS-31 protects mitochondria from oxidative damage and restores bioenergetic capacity, addressing one of the fundamental drivers of aging. Half-Life ~4 hours Typical Dose 0.25–4 mg Frequency Once daily Cycle Length 4-12 weeks as studied in clinical trials

Dosing Information

Half-Life

~4 hours

Typical Dose

0.25–4 mg

Frequency

Once daily

Cycle Length

4-12 weeks as studied in clinical trials

Administration Routes:

subcutaneousintravenous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

Developed by Stealth BioTherapeutics, elamipretide has been evaluated in multiple Phase 2 and 3 clinical trials. The TAZPOWER trial in Barth syndrome showed improvements in six-minute walk test distance. Studies in primary mitochondrial myopathy (MMPOWER) and heart failure (PROGRESS-HF) have shown mixed results, though biomarker improvements were noted. Preclinical data strongly support mitochondrial protection against age-related decline, ischemia-reperfusion injury, and neurodegenerative conditions.